-
- U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- Takeda (TSE:4502/NYSE:TAK ) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1,...
- 08월 06일 10:43
-
- L&F Achieves Record-High Quarterly Shipments, Begins LFP Supply for North American ESS in Q3 Advancing its Two-Track NCM and LFP Growth Strategy
- L&F, a global battery materials company, achieved record-high quarterly shipments driven by expanded sales of high-nickel cathode materials. The company expects annual NCM shipments to significantly surpass ...
- 08월 06일 17:30
-
- L&F Achieves Record-High Quarterly Shipments, Begins LFP Supply for North American ESS in Q3 Advancing its Two-Track NCM and LFP Growth Strategy
- L&F, a global battery materials company, achieved record-high quarterly shipments driven by expanded sales of high-nickel cathode materials. The company expects annual NCM shipments to significantly surpass ...
- 08월 06일 17:30
